Emory vs. Vanderbilt FACE-OFF: Novel Therapies Demonstrate Efficacy in Relapsed/Refractory Hematologic Malignancies

A summary of key discussion points and an overview of the evidence presented to inform the dialogue.

Examine outcomes such as overall survival, progression-free survival, and response rates in multiple myeloma patients who have experienced biochemical or clinical progression after prior lines of therapy.

Present real-world data on the efficacy and safety of the ixazomib-lenalidomide-dexamethasone combination in patients with relapsed/refractory multiple myeloma outside of clinical trials.

Compare outcomes between ide-cel chimeric antigen receptor T-cell (CAR-T) therapy and standard treatment regimens such as pomalidomide and daratumumab combinations in patients with heavily pretreated relapsed and refractory multiple myeloma.

Present initial results from the Phase 1 RedirecTT-1 trial exploring the combination of teclistamab and talquetamab in relapsed/refractory multiple myeloma.

Examine the efficacy and safety of the BCMA-targeting bispecific antibody elranatamab as monotherapy and in combinations from the Phase 2 MagnetisMM-3 trial in patients with relapsed or refractory multiple myeloma.